ReviewTechnology in cancer research & treatment
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.
Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Preoperative prediction of parametrial invasion in early-stage cervical cancer: a radiomics nomogram fusing multi-parametric MRI and clinical biomarkers.Abdominal radiology (New York) · 2026Article
- Nationwide trends in surgery selection and minimally invasive surgery for cervical cancer with preoperative T1B1/T1B2 disease in Japan.International journal of clinical oncology · 2026Review
- Article
- Preserved Menstruation After Chemoradiotherapy in Stage IIIC1 Cervical Cancer: A Unique Case.Journal of clinical medicine · 2026Article
- Dosimetric impact of two multileaf collimator systems in simultaneous integrated boost volumetric modulated arc therapy for lymph node metastases in stage IIIC cervical cancer.Frontiers in oncology · 2026Article
- GSDMD Promotes Epithelial-Mesenchymal Transition and Lymph Node Metastasis in Cervical Cancer in vitro and in vivo.Journal of inflammation research · 2026Article
- The Evolving Role of Radiation Oncology in the Management of Uterine Cervical Carcinoma: A State-of-the-Art Review for Non-Radiation Oncologists.Life (Basel, Switzerland) · 2025Review
- Rationality of FIGO 2018 IIIC cervical cancer according to local tumor and pelvic lymph node metastatic extent-a cohort study.BMC women's health · 2025Article
- Re-evaluating prognostic factors for cervical cancer with lymph node metastasis: a Japanese multicenter cohort study based on FIGO 2018.International journal of clinical oncology · 2025Article
- Efficacy of integrating surgical interventions with chemoradiotherapy in managing stage IIIC cervical cancer.American journal of translational research · 2025Article
- Article
- Article
- A novel prognostic biomarker in progression free survival for patients with cervical cancer, glucose to c-reactive protein ratio (GCR).BMC cancer · 2024Article
- Treatment for locally resectable stage IIIC1r cervical cancer: surgery or chemoradiotherapy?BMC cancer · 2024Article
- Lumican is a potential predictor on the efficacy of concurrent chemoradiotherapy in cervical squamous cell carcinoma.Heliyon · 2023Article
- Article
- Treatment for Locally Resectable Stage IIIC1 Cervical Cancer: A Retrospective, Single-Institution Study.Healthcare (Basel, Switzerland) · 2023Article
- Cervical Cancer Screening among Female Refugees in Jordan: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2022Article
- Oxymatrine induces anti-tumor response in cervical cancer by modulating circ_0008460/miR-197-3p/ribonucleotide reductase subunit M2 (RRM2).Bioengineered · 2022Article
- Dynamic Nomogram Based on the Metastatic Number and Sites and Therapy Strategies Predicting the Prognosis of Patients with Metastatic Cervical Cancer.International journal of women's health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is the fourth most common malignant tumor globally in terms of morbidity and mortality. The presence of lymph node metastasis (LNM) is an independent prognostic factor for progression-free survival (PFS) and overall survival (OS) in cervical cancer patients. The International Federation of Gynecology and Obstetrics (FIGO) staging system was revised in 2018. An important revision designates patients with regional LNM as stage IIIC, pelvic LNM only as stage IIIC1, and para-aortic LNM as stage IIIC2. However, the current staging system is only based on the anatomical location of metastatic lymph nodes (LNs). It does not consider other LN status parameters, which may limit its prognostic significance to a certain extent and needs further exploration and confirmation in the future. The purpose of this review is to summarize the choice of treatment for stage IIIC cervical cancer and the effect of different LN status parameters on prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.